Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 Dec 18;8(1):2166.

Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. 2017 Oct 9;32(4):411-426. PMCID: In Process

Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A. Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis. Cancer Res. 2017 Oct 1;77(19):5272-5286. PMCID: PMC5772763

Yamanaka K, Chatterjee N, Hemann MT, Walker GC. Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? PLoS Genet. 2017 Aug 17;13(8):e1006842. PMCID: PMC5560539

Ramos A, Hemann MT. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Cell. 2017 Jul 27;170(3):411-413.

Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich JN. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017 Jul 20;547(7663):355-359. PMCID: In Process

*Flamme M, Cressey PB, Lu C, Bruno PM, Eskandari A, Hemann MT, Hogarth G, Suntharalingam K. Induction of Necroptosis in Cancer Stem Cells using a Nickel(II)-Dithiocarbamate Phenanthroline Complex. Chemistry. 2017 May 26. PMCID: In Process

*Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes Dev. 2017 May 15;31(10):973-989. PMCID: PMC5495126

*Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017 Apr;23(4):461-471. PMCID: PMC5520548

*Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar;23(3):301-313. PMCID: PMC5540325


*Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K. The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. Dalton Trans. 2016 Nov 28;45(44):17867-17873. PMCID: In Process

*Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B. Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep. 2016 Nov 7;6:36198. PMCID: PMC5098152

*Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ. Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. Inorganica Chim Acta. 2016 Oct 1;452:125-129. PMCID: PMC5094802

*Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. PMCID: PMC5399143

*Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA. Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. J Am Chem Soc. 2016 Sep 28;138(38):12494-501. PMCID: PMC5597434

*Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K. The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells. Chembiochem. 2016 Sep 15;17(18):1713-8. PMCID: In Process

Braun CJ, Hemann MT. Rewiring the solid tumor epigenome for cancer therapy. Expert Rev Anticancer Ther. 2016 Sep;16(9):977-87.

*Bent EH, Gilbert LA, Hemann MT. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev. 2016 Aug 15;30(16):1811-21. PMCID: PMC5024680

*Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3892-900. PMCID: PMC4941480

*Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 Jun 27;213(7):1285-306. PMCID: PMC4925018

*Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell. 2016 Mar 24;165(1):234-46. PMCID: PMC5152932

*Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2845-50. PMCID: In Process


*Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. J Am Chem Soc. 2015 Dec 2;137(47):14854-7. PMCID: PMC4772771

*Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cancer Cell. 2015 Oct 20. PMCID: PMC4830093

McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Res. 2015 Aug 1;75(15):3127-38. PMCID: PMC4526337

Hemann M. Syngeneic Transplants with Modified Chimeric Hematopoietic Tumors. Cold Spring Harb Protoc. 2015 Aug 3;2015(8):735-9.

Hemann M. Loss-of-Function Screening in Hematopoietic Malignancies. Cold Spring Harb Protoc. 2015 Aug 3;2015(8):740-2.

Hemann M. Chimeric Tumor and Organ Transplantation Models. Cold Spring Harb Protoc. 2015 Aug 3;2015(8):725-30.

Zender L, Hemann M. Reconstitution of Mice with Modified Liver Stem Cells. Cold Spring Harb Protoc. 2015 Jul 1;2015(7):685-8.

Hemann M. Reconstitution of Mice with Modified Hematopoietic Stem Cells. Cold Spring Harb Protoc. 2015 Jul 1;2015(7):679-84.

Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med. 2015 Mar 9. PMCID: PMC4403045

*Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ. Necroptosis-inducing rhenium(v) oxo complexes. J Am Chem Soc. 2015 Mar 4;137(8):2967-74. PMCID: PMC4702498

*Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, Fenouille N, Zuber J, Williams RT, Young RA, Hemann MT. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes Dev. 2015 Mar 1;29(5):483-8. PMCID: PMC4358400

*Shingleton JR, Hemann MT. The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies. PLoS One. 2015 Nov 20;10(11). PMCID: PMC4654476


*Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. J Am Chem Soc. 2014 Oct 15;136(41):14413-6. PMCID: PMC4210142

*Zhao B, Hemann MT, Lauffenburger DA. Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4288. PMCID: PMC4205616

*Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29): 10773-8. PMCID: PMC4115561

Hemann MT. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov. 2014 May;4(5):516-8. PMCID: PMC4384127

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, Deangelo DJ, Hemann MT, Stegmaier K. SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell. 2014 Feb 10;25(2): 226-42. PMCID: PMC4106711

*Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014 Feb;4(2):166-74. PMCID: PMC3975231

*Pallasch C, Leskov I, Braun C, Vorholt D, Drake A, Soto-Feliciano Y, Bent E, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel L, Wendtner C, Heukamp L, Kreuzer K, Hallek M, Chen J, Hemann M. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy. Cell. 2014 Jan 30;156(3):590-602. PMCID: PMC3975171


*Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ. Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J Am Chem Soc. 2013 Sep 25;135(38):14060-3. PMCID: PMC3791136

Wilson JL, Hemann MT, Fraenkel E, Lauffenburger DA. Integrated network analyses for functional genomic studies in cancer. Semin Cancer Biol. 2013 Aug;23(4):213-8. PMCID: PMC3844556

*Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA. Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst. 2013 Jul;9(7):1604-19. PMCID: PMC3945388

Braun CJ, Hemann MT. Unraveling tumor suppressor networks with in vivo RNAi. Cell Stem Cell. 2013 Jun 6;12(6):639-41.

Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013 Apr 30;2:e00358. PMCID: PMC3641523

Leskov I, Pallasch CP, Drake A, Iliopoulou BP, Souza A, Shen CH, Schweighofer CD, Abruzzo L, Frenzel LP, Wendtner CM, Hemann MT, Chen J. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 2013 Feb 21;32(8):1066-72. PMCID: PMC4117216

*Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):E170-9. PMCID: PMC3545813


*Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resist Updat. 2012 Oct;15(5-6):249-57. PMCID: PMC3975170

*Gilbert LA, Hemann MT. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev. 2012 Aug 1;26(15):1758-68. PMCID: PMC3418592

*Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. (2011). Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Res., 71(17), 5850-5858. PMCID: PMC3165087


Gilbert LA, Hemann MT. (2011). Chemotherapeutic resistance: surviving stressful situations. Cancer Res., 71(15), 5062-5066. PMCID: PMC3148403

Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. (2011). Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. J Immunol., 187(2), 664-675. PMCID: PMC3131471

*Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. (2011) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat. Chem. Biol., 7(2), 92-100. PMCID: PMC3070540

2010 and earlier

*Xie K, Doles J, Hemann MT, Walker GC. (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc. Natl. Acad. Sci. USA, 107(48), 20792-20797. PMCID: PMC2996453

*Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. (2010) Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc. Natl. Acad. Sci. USA, 107(48), 20786-20791. PMCID: PMC2996428

Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T. (2010). Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature., 468(7323), 572-557. PMCID: PMC3003305

*Gilbert LA, Hemann MT. (2010) DNA damage-mediated induction of a chemoresistant niche. Cell, 143(3), 355-366. PMCID: PMC2972353

*Doles J and Hemann MT. NEK4 status affects differential sensitivity to microtubule poisons. Cancer Res. 2010 Feb 1;70(3):1033-41. PMCID: PMC2946156

Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. Oct 6;16(4):324-35. PMCID: PMC2829755

Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. (2009). Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle., 8(19), 3112-3119. PMCID: PMC3057180

*Meacham CE, Ho E, Dubrovsky E, Gertler FB and Hemann MT. In Vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genetics, (2009) Oct;41(10): 1133-1137. PMCID: PMC2756700

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes & Development, (2009) Aug 15;23(16) 1895-1909. PMCID: PMC2725944

*Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. (2009). Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther., 8(8), 2183-2192. PMCID: PMC2779718

Burgess, D.J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W.R., Hannon, G.J., Lowe, S.W., Hemann, M.T. (2008). Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci, 105(26), 9053-9058. PMCID: PMC2435590.

Mayr, C., Hemann, M.T., Bartel, D. (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315(5818), 1576-1579.

Hemann, M.T. and Narita, M. (2007). Oncogenes and senescence: breaking down in the fast lane. Genes Dev, 21(1), 1-5.

Hemann, M.T. and Lowe, S.W. (2006). The p53-Bcl-2 connection. Cell Death Differ, 13(8), 1256-1259

Dickins, R., Hemann, M.T., Zilfou, J., Simpson, D., Ibarra, I., Hannon, G., Lowe, S.W. (2005). Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet, 37(11), 1289-1295.

Hemann, M.T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J., Cordon-Cardo, C., Cleveland, J., Tansey, W., Lowe, S.W. (2005). Evasion of the p53 tumor surveillance network by tumor-derived MYC mutants. Nature, 436(7052), 807-811.

He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. (2005). A microRNA polycistron as a potential human oncogene. Nature., 435(7043), 828-833.

Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. (2005). A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep., 6(2), 177-183.

Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature., 430(7001), 797-802.

Chiang YJ, Hemann MT, Hathcock KS, Tessarollo L, Feigenbaum L, Hahn WC, Hodes RJ. (2004). Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol., 24(16), 7024-7031.

Hemann, M.T., Zilfou, J., Zhao, Z., Burgess, D., Hannon, G., Lowe, S. (2004). Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci, 101(25), 9333-9338.

Rabinowicz PD, Palmer LE, May BP, Hemann MT, Lowe SW, McCombie WR, Martienssen RA. (2003). Genes and transposons are differentially methylated in plants, but not in mammals. Genome Res., 13(12), 2658-2664.

O'Hearn SF, Huang CE, Hemann M, Zhelonkina A, Sollner-Webb B. (2003). Trypanosoma brucei RNA editing complex: band II is structurally critical and maintains band V ligase, which is nonessential. Mol Cell Biol., 23(21), 7909-7919.

Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW. (2003). Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res., 63(18), 5703-5706.

Hemann, MT, Fridman, J, Zilfou, J, Hernando, E, Paddison, P, Cordon-Cardo, C, Hannon, G, Lowe, S (2003). An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet, 33(3), 396-400.

Hemann, MT, Hathcock, K, Opperman, K, Strong, M, Greider, C, Hodes, R (2002). Haploinsufficiency of mTR results in defects in telomere elongation. Proc Natl Acad Sci, 99(6), 3591-3596.

Hemann MT, Strong MA, Hao LY, Greider CW. (2001). The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell., 107(1), 67-77.

Hemann, MT, Rudolph, K, Strong, M, DePinho, R, Chin, L, Greider, C (2001). Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Mol Biol of the Cell, 12, 2023-2030.

Rusché LN, Huang CE, Piller KJ, Hemann M, Wirtz E, Sollner-Webb B. (2001). The two RNA ligases of the Trypanosoma brucei RNA editing complex: cloning the essential band IV gene and identifying the band V gene. Mol Cell Biol., 21(4), 979-989.

Hemann MT, Greider CW. (2000). Wild-derived inbred mouse strains have short telomeres. Nucleic Acids Res., 28(22), 4474-4478.

Hemann MT, Hackett J, IJpma A, Greider CW. (2000). Telomere length, telomere-binding proteins, and DNA damage signaling. Cold Spring Harb Symp Quant Biol., 65, 275-279.

Hemann MT, Greider CW. (1999). G-strand overhangs on telomeres in telomerase-deficient mouse cells. Nucleic Acids Res., 27(20), 3964-3969.

Wagstaff J, Hemann M. (1995). A familial "balanced" 3;9 translocation with cryptic 8q insertion leading to deletion and duplication of 9p23 loci in siblings. Am J Hum Genet., 56(1), 302-309.


* papers arising from a supervised thesis